Rigel Pharmaceuticals Pays $70M Upfront for Global Vepdegestrant License from Arvinas, Pfizer
Summary
Rigel Pharmaceuticals has secured exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant) for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer from Arvinas and Pfizer. The agreement includes a $70 million upfront payment, an additional $15 million upon transition completion, and potential regulatory and sales milestones up to $320 million, alongside tiered royalties. Rigel will also reimburse Pfizer up to $40 million for certain development activities. This substantial licensing deal, representing a material investment for Rigel, strategically expands its oncology pipeline and provides a new growth avenue following recent negative Q1 earnings and the termination of its collaboration with Eli Lilly. Traders will be watching for HSR clearance and further development updates on VEPPANU.
At the time of this announcement, RIGL was trading at $30.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $543.4M. The 52-week trading range was $17.65 to $52.24. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.